EMA accepts Intas Pharma’s MAA for DMB-3115

herapeutic equivalence and safety confirmed between DMB-3115 and Stelara in global phase III 

Intas Pharma announced that the European Medicine Agency (EMA) confirms acceptance of the Marketing Authorisation Application (MAA) for DMB-3115, a biosimilar of Stelara (Ustekinumab). The MAA has been submitted by Accord Healthcare, a wholly owned subsidiary of Intas Pharma on June 23rd, and the EMA accepted the MAA submission on 14th July.

Dong-A Socio Holdings and Meiji Seika Pharma began joint development for DMB-3115 in 2013, and the rights for R&D and commercialisation were transferred from Dong-A Socio Holdings to Dong-A ST in July 2020 for efficient project management. In July 2021, Dong-A ST and Meiji Seika Pharma signed an exclusive, global license agreement with Intas Pharma and granted exclusive worldwide commercialisation rights excluding Korea, Japan, and some Asian countries. Intas Pharma is set to commercialise DMB-3115 with its global subsidiaries – Accord BioPharma of the US and Accord Healthcare of the EU, UK, and Canada.

The MAA submission is based on results from the phase III multi-regional clinical trials in patients with plaque psoriasis. The primary endpoint was the rate of change in the Psoriasis Area and Severity Index (PASI) for skin symptoms. As a result, the therapeutic equivalence between DMB-3115 and the reference product was verified, and no safety issues were observed.

“We are truly excited by this partnership which, besides strengthening our existing biosimilar portfolio, also reinforces our long-term commitment towards bettering access to world-class biosimilar drugs for patients globally,” said Binish Chudgar, Vice Chairman and Managing Director of Intas Pharma

Paul Tredwell, Executive Vice President of Accord Healthcare said, “We are delighted to reinforce our partnership with Dong-a & Meiji for Accord Healthcare to file for global rights to this critical drug reinforcing our commitment to improving access to high-quality biosimilar drugs for patients globally.”

A spokesperson for Dong-A ST stated, “We will spare no effort to ensure DMB-3115 is supplied to the global market.”



biosimilardrug approvalEuropean Medicine Agency (Intas Pharma
Comments (0)
Add Comment